CG Oncology, Inc. (NASDAQ:CGON – Get Free Report) Director James Mulay sold 24,165 shares of the stock in a transaction on Friday, July 10th. The shares were sold at an average price of $75.16, for a total value of $1,816,241.40. Following the transaction, the director directly owned 24,165 shares of the company’s stock, valued at approximately $1,816,241.40. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
James Mulay also recently made the following trade(s):
- On Monday, June 15th, James Mulay sold 1,964 shares of CG Oncology stock. The shares were sold at an average price of $60.12, for a total value of $118,075.68.
- On Friday, April 17th, James Mulay sold 15,600 shares of CG Oncology stock. The shares were sold at an average price of $73.01, for a total value of $1,138,956.00.
CG Oncology Price Performance
Shares of NASDAQ CGON opened at $69.50 on Friday. The stock has a market capitalization of $6.13 billion, a PE ratio of -29.83 and a beta of 0.22. CG Oncology, Inc. has a one year low of $23.65 and a one year high of $77.00. The business’s fifty day moving average price is $65.23 and its 200-day moving average price is $61.21.
Institutional Investors Weigh In On CG Oncology
Several hedge funds and other institutional investors have recently modified their holdings of CGON. Wellington Management Group LLP lifted its holdings in shares of CG Oncology by 190.3% in the third quarter. Wellington Management Group LLP now owns 5,512,779 shares of the company’s stock worth $222,055,000 after buying an additional 3,613,885 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in CG Oncology by 116.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,443,144 shares of the company’s stock valued at $142,961,000 after acquiring an additional 1,854,386 shares in the last quarter. Seven Fleet Capital Management LP bought a new stake in CG Oncology during the 4th quarter worth approximately $62,909,000. Bank of America Corp DE increased its holdings in CG Oncology by 409.9% during the 2nd quarter. Bank of America Corp DE now owns 1,736,769 shares of the company’s stock worth $45,156,000 after acquiring an additional 1,396,170 shares during the period. Finally, State Street Corp lifted its stake in CG Oncology by 46.4% in the 4th quarter. State Street Corp now owns 2,996,695 shares of the company’s stock worth $124,423,000 after purchasing an additional 950,028 shares in the last quarter. 26.56% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
Several analysts have recently issued reports on CGON shares. Weiss Ratings reissued a “sell (d-)” rating on shares of CG Oncology in a research report on Monday, April 20th. Wolfe Research started coverage on shares of CG Oncology in a report on Tuesday, May 19th. They issued a “peer perform” rating for the company. Wall Street Zen downgraded shares of CG Oncology from a “hold” rating to a “sell” rating in a report on Saturday, April 25th. HC Wainwright reiterated a “buy” rating and issued a $100.00 price objective on shares of CG Oncology in a research note on Monday, May 18th. Finally, JPMorgan Chase & Co. boosted their target price on shares of CG Oncology from $91.00 to $96.00 and gave the company an “overweight” rating in a report on Monday, May 11th. Eleven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $81.73.
View Our Latest Research Report on CGON
CG Oncology Company Profile
CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.
Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.
Featured Articles
- Five stocks we like better than CG Oncology
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
- Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test
Receive News & Ratings for CG Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CG Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
